U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07938983) titled 'GH56 Monotherapy for Second-line Treatment of MTAP-Deleted ESCC' on Nov. 10.
Brief Summary: This is a Phase 2/3, open-label, multicenter study to evaluate the efficacy and safety of GH56 as a single agent in participants with advanced Esophageal Squamous Cell Carcinoma(ESCC) with methylthioadenosine phosphorylase (MTAP) deficiency in the second-line or later setting. In this seamlessly designed Phase 2/3 study, a single-arm Phase 2 study will be conducted first, and after favorable efficacy data are obtained, a Phase 3 study comparing against standard chemotherapy will then be conducted.
Study Start Date: Dec. 31
Study Type: INTER...